Korean Circ J.  2011 Jul;41(7):379-384. 10.4070/kcj.2011.41.7.379.

Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease

• Kim HK
• Oh J
• Hong YM
• Sohn S

• KMID: 2225101
• DOI: http://doi.org/10.4070/kcj.2011.41.7.379

Abstract

BACKGROUND AND OBJECTIVES
We sought to determine parameters to guide the decision of retreatment in patients with Kawasaki disease (KD) who remained febrile after initial intravenous immunoglobulin (IVIG).
SUBJECTS AND METHODS
A total of 129 children with KD were studied prospectively. Patients were treated with IVIG 2 to 9 days after the onset of disease. Laboratory measures, such as white blood cell (WBC), percentage of neutrophils, C-reactive protein (CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP), were determined before and 48 to 72 hours after IVIG treatment. Patients were classified into IVIG-responsive and IVIG-resistant groups, based on the response to IVIG.
RESULTS
Of a total of 129 patients, 107 patients (83%) completely responded to a single IVIG therapy and only 22 patients (17%) required retreatment: 14 had persistent fever and 8 had recrudescent fever. There was no significant difference between the groups in age, gender distribution, and duration of fever to IVIG initiation, but coronary artery lesions developed significantly more often in the resistant group than in the responsive group (31.8% vs. 2.8%, p=0.000). Compared with pre-IVIG data, post-IVIG levels of WBC, percentage of neutrophils, CRP, and NT-proBNP decreased to within the normal range in the responsive group, whereas they remained high in the resistant group. Multivariate logistic regression indicated that neutrophil counts, CRP, and NT-proBNP were independent parameters of retreatment.
CONCLUSION
Additional therapy at an early stage of the disease should be administered for febrile patients who have high values of CRP, NT-proBNP, and/or neutrophil counts after IVIG therapy.

Keyword

Kawasaki disease; Intravenous immunoglobulins; Retreatment

MeSH Terms

C-Reactive Protein
Child
Coronary Vessels
Fever
Humans
Immunization, Passive
Immunoglobulins
Immunoglobulins, Intravenous
Leukocytes
Logistic Models
Mucocutaneous Lymph Node Syndrome
Natriuretic Peptide, Brain
Neutrophils
Peptide Fragments
Prospective Studies
Reference Values
Retreatment
C-Reactive Protein
Immunoglobulins
Immunoglobulins, Intravenous
Natriuretic Peptide, Brain
Peptide Fragments

Reference

1. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986. 315:341–347.

2. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998. 17:1144–1148.

3. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000. 105:E78.

4. Reller M, DeCristofaro J, Schwartz DC. Coronary aneurysms in a patient with atypical Kawasaki syndrome and a streptococcal infection. Pediatr Cardiol. 1984. 5:205–207.

5. Johnson D, Azimi P. Kawasaki disease associated with Klebsiella pneumoniae bacteremia and parainfluenza type 3 virus infection. Pediatr Infect Dis. 1985. 4:100.

6. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin retreatment in Kawasaki disease. J Pediatr. 1993. 123:657–659.

7. Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993. 87:1776–1780.

8. Research committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. 1984. Tokyo: Ministry of Health and Welfare.

9. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr. 2000. 137:177–180.

10. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr. 2000. 137:172–176.

11. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006. 113:2606–2612.

12. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005. 146:662–667.

13. Song MS, Lee SB, Sohn S, et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J. 2010. 40:334–338.

14. Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr. 2004. 144:496–499.

15. Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr. 2002. 140:450–455.

16. Suzuki H, Noda E, Miyawaki M, Tacheuchi T, Uemura S, Koike M. Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatr Int. 2001. 43:115–119.

17. Samada K, Igarashi H, Shiraishi H, Hatake K, Momoi MY. Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease. Eur J Pediatr. 2002. 161:538–541.

18. Hamamichi Y, Ichida F, Yu X, et al. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions. Pediatr Res. 2001. 49:74–80.

19. Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005. 47:305–310.

20. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004. 110:2747–2771.

21. Lee H, Kim H, Kim HS, Sohn S. NT-pro BNP: a new diagnostic screening tool for Kawasaki disease. Korean J Pediatr. 2006. 49:539–544.

22. Dahdah N, Siles A, Fournier A, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol. 2009. 30:810–817.